Log in

PAVmed Stock Price, Forecast & Analysis (NASDAQ:PAVM)

$0.89
+0.03 (+3.49 %)
(As of 11/19/2019 06:25 AM ET)
Today's Range
$0.86
Now: $0.89
$0.89
50-Day Range
$0.86
MA: $0.91
$0.97
52-Week Range
$0.81
Now: $0.89
$1.38
Volume230,400 shs
Average Volume142,151 shs
Market Capitalization$27.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PAVM
CUSIPN/A
Phone212-949-4319

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.17) per share

Profitability

Net Income$-17,970,000.00

Miscellaneous

Employees9
Market Cap$27.93 million
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable

Receive PAVM News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.


PAVmed (NASDAQ:PAVM) Frequently Asked Questions

What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

How were PAVmed's earnings last quarter?

PAVmed Inc (NASDAQ:PAVM) announced its earnings results on Thursday, November, 15th. The company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.04. View PAVmed's Earnings History.

When is PAVmed's next earnings date?

PAVmed is scheduled to release their next quarterly earnings announcement on Thursday, November 21st 2019. View Earnings Estimates for PAVmed.

What price target have analysts set for PAVM?

1 brokerages have issued 12 month price objectives for PAVmed's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate PAVmed's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 237.1% from the stock's current price. View Analyst Price Targets for PAVmed.

What is the consensus analysts' recommendation for PAVmed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PAVmed.

Has PAVmed been receiving favorable news coverage?

Media coverage about PAVM stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PAVmed earned a news sentiment score of -3.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for PAVmed.

Are investors shorting PAVmed?

PAVmed saw a drop in short interest during the month of October. As of October 15th, there was short interest totalling 616,900 shares, a drop of 18.3% from the September 15th total of 755,300 shares. Based on an average daily volume of 120,800 shares, the days-to-cover ratio is currently 5.1 days. Currently, 2.6% of the shares of the company are sold short. View PAVmed's Current Options Chain.

Who are some of PAVmed's key competitors?

What other stocks do shareholders of PAVmed own?

Who are PAVmed's key executives?

PAVmed's management team includes the folowing people:
  • Dr. Lishan Aklog M.D., Chairman & CEO (Age 53)
  • Mr. Dennis M. McGrath CPA, Pres, CFO & Sec. (Age 62)
  • Dr. Brian J. deGuzman M.D., Chief Medical Officer (Age 54)
  • Mike Havrilla, Director of Investor Relations
  • Mr. Shaun M. O'Neil, Chief Commercial Officer

Who are PAVmed's major shareholders?

PAVmed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Glassman Wealth Services (0.10%). Company insiders that own PAVmed stock include Dennis M Mcgrath, Ira Scott Greenspan and Lishan Aklog. View Institutional Ownership Trends for PAVmed.

Which major investors are buying PAVmed stock?

PAVM stock was acquired by a variety of institutional investors in the last quarter, including Glassman Wealth Services. Company insiders that have bought PAVmed stock in the last two years include Dennis M Mcgrath and Lishan Aklog. View Insider Buying and Selling for PAVmed.

How do I buy shares of PAVmed?

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PAVmed's stock price today?

One share of PAVM stock can currently be purchased for approximately $0.89.

How big of a company is PAVmed?

PAVmed has a market capitalization of $27.93 million. PAVmed employs 9 workers across the globe.View Additional Information About PAVmed.

What is PAVmed's official website?

The official website for PAVmed is http://www.pavmed.com/.

How can I contact PAVmed?

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected]


MarketBeat Community Rating for PAVmed (NASDAQ PAVM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about PAVmed and other stocks. Vote "Outperform" if you believe PAVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel